Other variant appears to be related to recurrence of progesterone receptor-positive disease
Monday, December 13, 2010 (Last Updated: 12/14/2010)
MONDAY, Dec. 13 (HealthDay News) -- A polymorphic variant in human histone deacetylase 9 (HDAC9) appears to be associated with an earlier onset of estrogen receptor (ER) positive breast cancer, while another variant may be associated with recurrence of progesterone receptor-positive disease, according to a study presented at the annual San Antonio Breast Cancer Symposium, held from Dec. 8 to 12.
Kim M. Hirshfield, M.D., Ph.D., and Alexei Vazquez, Ph.D., of the University of Medicine and Dentistry New Jersey-Robert Wood Johnson Medical School in New Brunswick, evaluated the association of human HDAC9 single nucleotide polymorphisms at three loci (rs2239926, rs2240279, and rs2286003) with age of onset and recurrence of breast cancer in a cohort of 1,101 patients enrolled prospectively from 2004 to 2009. They performed genotyping using an Applied Biosystems TaqMan assay on the ABI 7900HT Fast Real-Time PCR System. They studied the association between HDAC9 genotypes and age at diagnosis in the 516 Caucasian women with ductal carcinomas.
In patients with ER-positive breast cancer, the investigators found that those with the homozygous variant CC at HDAC9 rs2239926 locus developed breast cancer at an earlier age (49.3 years) than G allele carriers (GG+CG) (54.1 years). However, in patients with ER-negative breast cancer, those with the homozygous variant CC at HDAC9 rs2239926 locus developed breast cancer at a later age (53.7 years) than G allele carriers (GG+CG) (48.0 years). Another polymorphism, HDAC9 rs2240279 demonstrated a strong association with recurrence in Caucasians with progesterone receptor-positive breast cancers.
"These genetic variants in the HDAC9 gene could ultimately affect signaling through the estrogen receptor, thus possibly leading to the alteration of the clinical features of breast cancer. The more specifics we have about how genetics alter age of diagnosis and natural biology of breast cancer could help us to better tailor treatment options in the future," Hirshfield said in a statement.
Copyright © 2010 HealthDay. All rights reserved.